Since his return to the White House, President Donald Trump has acted quickly in implementing his sweeping immigration agenda, which has emerged as a tentpole in all of his presidential campaigns.

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

President Trump’s first year back in office saw a whirlwind of executive actions, the passage of a major reconciliation bill and the rapid remaking of the federal government. Trump campaigned in 2024 ...

Wells Fargo initiated coverage of Arcellx (ACLX) with an overweight rating saying that its experimental CAR-T therapy for multiple myeloma, anito-cel, is a "future pillar" in management of the blood ...

More for You America’s biggest oil field is turning into a pressure cooker Fallout: Investigators trace alleged fraud Russian forces near collapse in Kupyansk as Moscow allies concede city lost: ...

TAOS COUNTY, N.M. (KRQE) – The state is making a new commitment to make the Rio Grande Gorge Bridge safer and keep people from taking their lives. That announcement was made on Friday as advocates are ...

1 Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China 2 Department of Hematology, Affiliated Hospital of Zunyi Medical ...

NEW YORK – At the American Society of Hematology's annual meeting this week, two groups of researchers from Spain’s Clinica Universidad de Navarra showed that circulating tumor cells (CTCs) may have ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

Early results from the LINKER-MM4 trial reveal promising response rates for linvoseltamab in newly diagnosed multiple myeloma patients, with manageable side effects. Robert Orlowski, M.D., Ph.D., of ...